Your browser is no longer supported. Please, upgrade your browser.
Settings
APEN Apollo Endosurgery, Inc. daily Stock Chart
APEN [NASD]
Apollo Endosurgery, Inc.
Index- P/E- EPS (ttm)-21.83 Insider Own24.50% Shs Outstand17.67M Perf Week5.17%
Market Cap111.50M Forward P/E- EPS next Y-1.19 Insider Trans20.98% Shs Float15.53M Perf Month58.54%
Income-32.80M PEG- EPS next Q-0.34 Inst Own67.80% Short Float1.43% Perf Quarter18.16%
Sales63.80M P/S1.75 EPS this Y30.40% Inst Trans-8.22% Short Ratio0.90 Perf Half Y4.30%
Book/sh3.67 P/B1.72 EPS next Y39.30% ROA- Target Price10.83 Perf Year-63.19%
Cash/sh1.96 P/C3.22 EPS next 5Y- ROE- 52W Range3.55 - 17.48 Perf YTD12.68%
Dividend- P/FCF- EPS past 5Y-31.70% ROI-25.90% 52W High-63.91% Beta0.48
Dividend %- Quick Ratio2.00 Sales past 5Y47.20% Gross Margin62.90% 52W Low77.75% ATR0.32
Employees193 Current Ratio2.50 Sales Q/Q4.40% Oper. Margin- RSI (14)71.34 Volatility4.47% 6.13%
OptionableNo Debt/Eq0.58 EPS Q/Q98.70% Profit Margin- Rel Volume0.20 Prev Close6.31
ShortableYes LT Debt/Eq0.58 EarningsJan 25 AMC Payout- Avg Volume245.68K Price6.31
Recom2.00 SMA2016.38% SMA5033.71% SMA2004.09% Volume48,268 Change0.00%
Jan-04-18Resumed ROTH Capital Buy $9.50
Sep-26-17Initiated Northland Capital Outperform $12
Aug-02-17Initiated ROTH Capital Buy $10
Dec-01-17 09:02AM  The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx Zacks
Nov-28-17 10:57AM  Apollo Endosurgery Inc (APEN) Sparks Optimism Among Investors; Heres Why SmarterAnalyst +32.68%
07:49AM  Apollo Endosurgery's stock rockets on FDA clearance of OverStitch Sx MarketWatch
Nov-27-17 04:01PM  Apollo Endosurgery Receives FDA Clearance for OverStitch Sx Endoscopic Suturing System Business Wire
Nov-17-17 04:01PM  Apollo Endosurgery to Present at the 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-16-17 04:59PM  David C. Pacitti Joins Apollo Endosurgery Board of Directors Business Wire
Nov-01-17 09:36AM  Apollo Endosurgery, Inc. :APEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 Capital Cube +5.34%
Oct-30-17 08:00AM  Apollo Endosurgery Announces Presentation of the Brazilian Intragastric Balloon Consensus Statement at ObesityWeek Business Wire
Oct-26-17 04:01PM  Apollo Endosurgery, Inc. Reports Third Quarter 2017 Results Business Wire -5.96%
Oct-24-17 06:12PM  Apollo Endosurgery and American Gastroenterological Association to Establish Endoscopic Suturing Procedure Registry Business Wire
Oct-19-17 04:01PM  Apollo Endosurgery to Report Third Quarter 2017 Financial Results on October 26, 2017 Business Wire
Oct-06-17 09:07AM  Apollo Endosurgery, Inc. :APEN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-19-17 04:01PM  Apollo Endosurgery to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Aug-31-17 04:02PM  Apollo Endosurgery Announces 20-year LAP-BAND® Outcomes Data Presented at 22nd IFSO World Congress in London Business Wire
Aug-30-17 04:01PM  Apollo Endosurgery Announces CE Mark Approval for the ORBERA365 Managed Weight Loss System, Expanding the Indwell Period from 6 Months to 12 Months with the Gastric Balloon Category Leader Business Wire
Aug-10-17 11:29PM  Apollo Endosurgery Provides Update and Clarity to FDA Letter to Health Care Providers Related to Potential Risks of Intragastric Balloons Business Wire -25.80%
Aug-01-17 04:01PM  Apollo Endosurgery, Inc. Reports Second Quarter 2017 Results Business Wire
Jul-26-17 09:00AM  Apollo Endosurgery to Report Second Quarter 2017 Financial Results on August 1, 2017 Business Wire
Jul-25-17 04:01PM  Apollo Endosurgery, Inc. Announces Closing of Public Offering and Underwriters Full Exercise of Over-Allotment Option Business Wire
Jul-20-17 07:00AM  Apollo Endosurgery, Inc. Announces Pricing of $31 Million Public Offering Business Wire
Jul-14-17 11:40AM  Apollo Endosurgery Gears Up for Secondary Offering 24/7 Wall St. -6.78%
Jul-12-17 05:45AM  Apollo Endosurgery, Inc. Reports Preliminary Unaudited Financial Estimates for the Second Quarter of 2017 Business Wire -14.45%
May-05-17 11:06AM  Apollo Endosurgery, Inc. :APEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 Capital Cube
May-04-17 08:34AM  Apollo Endosurgery, Inc. Reports First Quarter 2017 Results Business Wire -13.61%
May-02-17 04:57PM  Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Digestive Disease Week® 2017 Conference (DDW) Business Wire -19.95%
10:21AM  Apollo Endosurgery to Report First Quarter 2017 Financial Results on May 4, 2017 Business Wire
Apr-19-17 09:24AM  Apollo Endosurgery, Inc. :APEN-US: Earnings Analysis: Q4, 2016 By the Numbers : April 19, 2017 Capital Cube
Mar-09-17 03:31PM  Apollo Endosurgery, Inc. to Participate at the 29th Annual ROTH Conference Business Wire
Mar-08-17 04:02PM  Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2016 Results Business Wire -6.02%
Mar-06-17 03:00PM  Apollo Endosurgery to Report Fourth Quarter and Full Year 2016 Financial Results on March 8, 2017 Business Wire
Jan-17-17 06:00AM  Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer Business Wire -8.55%
Jan-03-17 11:10AM  Tuesdays Biggest Biotech and Pharma Moves 24/7 Wall St. +41.86%
Dec-30-16 01:15PM  Apollo Endosurgery Shares Up 20% After Going Public With Reverse Merger TheStreet.com -24.54%
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STONEPINE CAPITAL, L.P.10% OwnerJan 03Buy5.786,33936,6562,577,996Jan 03 05:33 PM
STONEPINE CAPITAL, L.P.10% OwnerJan 02Buy5.7311,34364,9602,571,657Jan 03 05:33 PM
STONEPINE CAPITAL, L.P.10% OwnerDec 29Buy5.565,16328,7172,560,314Jan 03 05:33 PM
STONEPINE CAPITAL, L.P.10% OwnerDec 26Buy5.005,28726,4352,555,151Dec 28 05:03 PM
STONEPINE CAPITAL, L.P.10% OwnerDec 22Buy5.0041,399206,8632,549,864Dec 22 05:26 PM
STONEPINE CAPITAL, L.P.10% OwnerDec 21Buy4.9498,324485,9472,508,465Dec 22 05:26 PM
STONEPINE CAPITAL, L.P.10% OwnerDec 20Buy4.5045,434204,3122,410,141Dec 22 05:26 PM
Schwartzhoff BretV.P. U.S. Sales and MarketingNov 07Buy4.249,50040,28015,631Nov 09 07:10 PM
PTV SCIENCES II L P10% OwnerSep 12Buy3.85135,000519,7501,266,909Sep 25 03:50 PM
Anderson Rick DDirectorSep 12Buy3.85135,000519,7501,266,909Sep 25 03:15 PM
Crawford Matthew SDirectorSep 12Buy3.85135,000519,7501,266,909Sep 25 03:23 PM
Crawford Matthew SDirectorSep 05Buy4.0441,000165,6401,131,909Sep 25 03:23 PM
Anderson Rick DDirectorSep 05Buy4.0441,000165,6401,131,909Sep 25 03:15 PM
PTV SCIENCES II L P10% OwnerSep 05Buy4.0441,000165,6401,131,909Sep 25 03:50 PM